Mark Godsy, CEO and co-founder and Dr. Alan Shackelford, co-founder of Shackelford Pharmaceuticals, sat down to discuss using real-world data to guide cannabinoid-based drug development at the Benzinga Capital Cannabis Conference in Chicago.
Shackelford Pharma is a clinical-stage biopharmaceutical company developing medicines for neurological diseases with significant unmet patient needs. Its first drug candidate is targeted for use in the treatment of seizure disorders and is scheduled to enter a Phase 2 trial in Q2 2023.
Dr. Shackelford initially gained national attention for his breakthrough treatment of a young Dravet Syndrome patient with cannabinoids. The company has since leveraged real-world data from its clinical practice to guide its development decisions. The company’s research and development team has been involved in 43 FDA drug approvals, including six anti-epileptic drugs.
Watch Exclusive Footage Here
Interested in learning more about the Benzinga Cannabis Capital Conference? Get more information here.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!